The BsAb demonstrated potent anti-tumor effects through two distinct mechanisms: inhibition of c-MET signal transduction and promoting macrophage-mediated phagocytosis; promised as a novel therapeutic option for patients with c-MET/PD-L1+ CRC, the status of exosomal-c-MET/PD-L1 may serve as a biomarker for predicting responsiveness to BsAb treatment (39). Here, MET is linked to neoplasm.